Vaaji, a pioneer in smart pharmaceutical therapeutics, announced the successful completion of a pilot study conducted in collaboration with the Penn Artificial Intelligence and Technology Collaboratory (PennAITech) at the University of Pennsylvania. The exploratory study, part of the AI/Tech + Aging (A2) Collective funded by the National Institute on Aging (NIA), achieved 100% technical accuracy in monitoring patch status, validating Vaaji's proprietary smart patch system as a robust tool with the potential to significantly improve safety in transdermal drug delivery.
Transdermal patches are a vital delivery mechanism for medications treating Alzheimer's (such as rivastigmine), Parkinson's, and pain management. However, in real-world scenarios, patients or overwhelmed caregivers may accidentally apply a new patch without removing the old one ("patch stacking") or forget applications entirely. In active therapy, this can lead to ineffective treatment or potentially life-threatening overdoses. Vaaji is developing a solution to transform standard passive patches into "smart" therapeutics by leveraging advanced Internet of Things (IoT) sensors and Artificial Intelligence, designed to provide real-time visibility into medication adherence.
The proof-of-concept study enrolled 51 healthy volunteers using placebo patches to evaluate the system's detection capabilities against manual oversight. The results confirmed the platform's technical reliability, including 100% agreement between Vaaji's remote monitoring data and site investigator records (REDCap), matching the "gold standard" of direct human supervision. The system also successfully identified simulated "patch stacking" in real-time, validating the core technology required to prevent overdose events in future clinical applications. Additionally, the technology integrated smoothly into volunteers' daily routines, supporting the feasibility of the system for home-based care.
Patrick Mercier, Professor of Electrical and Computer Engineering at UCSD and Chief Technical Advisor at Vaaji, stated, "This study provides the first real-world evidence that our smart patch platform can deliver perfect accuracy in detecting patch application errors—a critical step toward enhancing patient safety in Alzheimer's care. We have proven that the underlying technology is robust, scalable, and ready for further development." William Z. Potter, MD, PhD, co-Principal Investigator and Chief Scientific Advisor at Vaaji, added, "The 100% agreement between remote monitoring and site investigator records is a landmark result for this early-stage development. It demonstrates that our system has the potential to match human oversight, paving the way for safer, smarter home care solutions." Sandeep Patil, MD, PhD, Co-founder of Vaaji, noted, "With the aging population growing rapidly, the need for technologies that enable safe, independent living is more urgent than ever. We are grateful for the support of the A2 Collective, PennAITech, and the NIA. These results strengthen our commitment to bringing these benefits to patients and caregivers."
The data from this pilot study will inform Vaaji's clinical and regulatory strategy as the company advances toward broader clinical trials involving active therapeutics. The company aims to establish its smart monitoring platform as a new safety standard for high-risk transdermal medications. For more information on Vaaji's patient-centric platform, visit www.vaaji.io.
